Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment
Authors
Keywords
-
Journal
SCIENCE
Volume 353, Issue 6303, Pages 1033-1036
Publisher
American Association for the Advancement of Science (AAAS)
Online
2016-09-02
DOI
10.1126/science.aaf9590
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models
- (2016) Melissa A Penny et al. LANCET
- Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies
- (2016) Laurent Coudeville et al. VACCINE
- Projected Impact of Dengue Vaccination in Yucatán, Mexico
- (2016) Thomas J. Hladish et al. PLoS Neglected Tropical Diseases
- Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study
- (2015) Chukiat Sirivichayakul et al. JOURNAL OF INFECTIOUS DISEASES
- Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults
- (2015) Beth D. Kirkpatrick et al. JOURNAL OF INFECTIOUS DISEASES
- Differential efficacy of dengue vaccine by immune status
- (2015) Isabel Rodriguez-Barraquer et al. LANCET
- Dengue vaccine: hypotheses to understand CYD-TDV-induced protection
- (2015) Bruno Guy et al. NATURE REVIEWS MICROBIOLOGY
- Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
- (2015) Sri Rezeki Hadinegoro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
- (2015) Luis Villar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Asymptomatic humans transmit dengue virus to mosquitoes
- (2015) Veasna Duong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modeling the impact on virus transmission of Wolbachia -mediated blocking of dengue virus infection of Aedes aegypti
- (2015) Neil M. Ferguson et al. Science Translational Medicine
- Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia
- (2015) Ilaria Dorigatti et al. VACCINE
- Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
- (2014) Maria Rosario Capeding et al. LANCET
- Revisiting Rayong: Shifting Seroprofiles of Dengue in Thailand and Their Implications for Transmission and Control
- (2013) Isabel Rodríguez-Barraquer et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil
- (2013) Gustavo H. Dayan et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Reduced Risk of Disease During Postsecondary Dengue Virus Infections
- (2013) Sandra Olkowski et al. JOURNAL OF INFECTIOUS DISEASES
- Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity
- (2013) N. G. Reich et al. Journal of the Royal Society Interface
- Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds
- (2013) Luis Á. Villar et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes
- (2013) N. M. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Challenges in the Interpretation of Dengue Vaccine Trial Results
- (2013) Isabel Rodriguez-Barraquer et al. PLoS Neglected Tropical Diseases
- Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
- (2012) Arunee Sabchareon et al. LANCET
- The Incubation Periods of Dengue Viruses
- (2012) Miranda Chan et al. PLoS One
- Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru
- (2012) Claudio F. Lanata et al. VACCINE
- Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years
- (2012) Yee Sin Leo et al. Human Vaccines & Immunotherapeutics
- Immune Response to Dengue Virus and Prospects for a Vaccine
- (2011) Brian R. Murphy et al. Annual Review of Immunology
- Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines
- (2011) Rosario Z. Capeding et al. VACCINE
- A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults
- (2010) Dennis Morrison et al. JOURNAL OF INFECTIOUS DISEASES
- The Effects of Tertiary and Quaternary Infections on the Epidemiology of Dengue
- (2010) Paul S. Wikramaratna et al. PLoS One
- CYTOPLASMIC INCOMPATIBILITY IN POPULATIONS WITH OVERLAPPING GENERATIONS
- (2009) Michael Turelli EVOLUTION
- “Guidelines for the clinical evaluation of dengue vaccines in endemic areas”: Summary of a World Health Organization Technical Consultation
- (2008) Robert Edelman et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More